J Bone Metab.  2017 May;24(2):91-96. 10.11005/jbm.2017.24.2.91.

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis

Affiliations
  • 1Department of Orthopaedic Surgery, Gyeongsang National University Hospital, Jinju, Korea.
  • 2Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Korea. hayongch@naver.com
  • 3Department of Orthopaedic Surgery, Ajou University College of Medicine, Suwon, Korea.
  • 4Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea.
  • 5Department of Orthopaedic Surgery, Konyang University Hospital, Daejeon, Korea.
  • 6Department of Orthopaedic Surgery, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea.
  • 7Department of Orthopaedic Surgery, Chungbuk National University College of Medicine, Cheongju, Korea.

Abstract

BACKGROUND
The purpose of this prospective, open-label, observational study was to assess the fracture preventing effect of Maxmarvil® tablets (alendronate 5 mg + calcitriol 0.5 µg) in patients with osteoporosis and to evaluate the change in bone mineral density (BMD) at the minimum 1-year follow-up.
METHODS
In this multicenter observational study, 691 patients with osteoporosis (aged 50 years or older) were treated with alendronate 5 mg + calcitriol 0.5 µg/day during their normal course of care. Patients were assessed at baseline and at 6 and 12 months. Baseline characteristics (including age, gender, concomitant disease, and baseline fractures) were evaluated.
RESULTS
From among the 848 participants, 149 individuals were lost to follow-up at the time of the study and 8 people had died. The 691 participants (54 men and 637 women) finished the follow-up study and completed the questionnaire. The mean age of the participants was 71.5 years (range, 50-92 years; mean age, 72.3 years for men and 71.4 years for women). Osteoporotic fracture occurred in 19 patients (2.7%). BMD of the lumbar spine and hip was improved by 5% and 1.5% at the latest follow-up. At the latest follow-up, 24 patients (3.5%) complained of drug-related complications such as dyspepsia, constipation, and nausea.
CONCLUSIONS
This prospective observational study demonstrated that alendronate 5 mg + calcitriol 0.5 µg/day had a preventive effect on osteoporotic fracture and it increased the BMD of the lumbar spine by 5% at the latest follow-up.

Keyword

Alendronate; Bone density; Calcitriol; Osteoporosis; Osteoporotic fractures

MeSH Terms

Alendronate
Bone Density
Calcitriol*
Constipation
Dyspepsia
Follow-Up Studies
Hip
Humans
Lost to Follow-Up
Male
Nausea
Observational Study
Osteoporosis*
Osteoporotic Fractures
Prospective Studies
Spine
Tablets*
Alendronate
Calcitriol
Tablets

Figure

  • Fig. 1 Flow of patients through the study.

  • Fig. 2 (A) Mean lumbar spine bone mineral density (BMD; g/cm2) and (B) mean hip BMD (g/cm2) after one year treatment with Maxmarvil®.


Reference

1. Ha YC, Kim TY, Lee A, et al. Current trends and future projections of hip fracture in South Korea using nationwide claims data. Osteoporos Int. 2016; 27:2603–2609.
Article
2. Lee SR, Ha YC, Kang H, et al. Morbidity and mortality in Jeju residents over 50-years of age with hip fracture with mean 6-year follow-up: a prospective cohort study. J Korean Med Sci. 2013; 28:1089–1094.
Article
3. Madureira MM, Ciconelli RM, Pereira RM. Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo). 2012; 67:1315–1320.
Article
4. Abimanyi-Ochom J, Watts JJ, Borgström F, et al. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). Osteoporos Int. 2015; 26:1781–1790.
Article
5. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29:744–751.
Article
6. Peng J, Liu Y, Chen L, et al. Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: a meta-analysis. Pak J Med Sci. 2016; 32:499–504.
Article
7. Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011; 96:1006–1014.
Article
8. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003; 14:722–727.
Article
9. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155.
Article
10. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523.
Article
11. Zhou J, Ma X, Wang T, et al. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016; 27:3289–3300.
Article
12. Rhee Y, Kang M, Min Y, et al. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int. 2006; 17:1801–1807.
Article
13. Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm. 2004; 10:142–151.
Article
14. Foster SA, Shi N, Curkendall S, et al. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013; 13:15.
Article
15. Modi A, Tang J, Sen S, et al. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. Curr Med Res Opin. 2015; 31:767–777.
Article
16. Iwamoto J, Takeda T, Sato Y, et al. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Metab. 2005; 23:238–242.
Article
17. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006; 91:2631–2637.
Article
18. Tan W, Sun J, Zhou L, et al. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. J Clin Pharm Ther. 2016; 41:519–523.
Article
19. Suh HW, Kim HO, Kim YS, et al. The efficacy and safety of a combined alendronate and calcitriol agent (Maxmarvil): a postmarketing surveillance study in Korean postmenopausal women with osteoporosis. Korean J Fam Med. 2012; 33:346–355.
Article
Full Text Links
  • JBM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr